Femke Jansen1, Irma M Verdonck-de Leeuw2,3, Eva Gamper4, Richard Norman5, Bernhard Holzner4, Madeleine King6, Georg Kemmler7. 1. Department of Otolaryngology-Head and Neck Surgery, Amsterdam UMC, Cancer Center Amsterdam, Vrije Universiteit Amsterdam, PO Box 7057, 1007 MB, Amsterdam, The Netherlands. f.jansen1@amsterdamumc.nl. 2. Department of Otolaryngology-Head and Neck Surgery, Amsterdam UMC, Cancer Center Amsterdam, Vrije Universiteit Amsterdam, PO Box 7057, 1007 MB, Amsterdam, The Netherlands. 3. Department of Behavioural and Movement Sciences, Section Clinical Psychology, Amsterdam Public Health, van der Boechorststraat 7, 1081 BT, Amsterdam, The Netherlands. 4. Department of Psychiatry, Psychotherapy and Psychosomatics, University Hospital Psychiatry II, Medical University of Innsbruck, Innsbruck, Austria. 5. School of Public Health, Curtin University, Perth, Australia. 6. School of Psychology, University of Sydney, Sydney, NSW, 2006, Australia. 7. Department of Psychiatry, Psychotherapy and Psychosomatics, University Hospital Psychiatry I, Medical University of Innsbruck, Innsbruck, Austria.
Abstract
PURPOSE: To measure utilities among cancer patients, a cancer-specific utility instrument called the European Organization for Research and Treatment of Cancer (EORTC) QLU-C10D has been developed based on EORTC quality of life core module (QLQ-C30). This study aimed to provide Dutch utility weights for the QLU-C10D. METHODS: A cross-sectional valuation study was performed in 1017 participants representative in age and gender of the Dutch general population. The valuation method was a discrete choice experiment containing 960 choice sets, i.e. pairs of QLU-C10D health states, each health state described in terms of the 10 QLU-C10D domains and the duration of that health state. Each participant considered 16 choice sets, choosing their preferred health state from each pair. Utility scores were derived using generalized estimation equation models. Non-monotonic levels were combined. RESULTS: Utility decrements were generated for all 10 QLU-C10D domains, with largest decrements for pain (- 0.242), physical functioning (- 0.228), and role functioning (- 0.149). Non-monotonic levels of emotional functioning, pain, fatigue, sleep problems, and appetite loss were combined. No decrement in utility was seen in case of a little or quite a bit impairment in emotional functioning or a little pain. The mean QLU-C10D utility score of the participants was 0.85 (median = 0.91, interquartile range = 0.82 to 0.96). CONCLUSION: Dutch utility decrements were generated for the QLU-C10D. These are important for evaluating the cost-utility of new cancer treatments and supportive care interventions. Further insight is warranted into the added value of the QLU-C10D alongside other utility instruments.
PURPOSE: To measure utilities among cancerpatients, a cancer-specific utility instrument called the European Organization for Research and Treatment of Cancer (EORTC) QLU-C10D has been developed based on EORTC quality of life core module (QLQ-C30). This study aimed to provide Dutch utility weights for the QLU-C10D. METHODS: A cross-sectional valuation study was performed in 1017 participants representative in age and gender of the Dutch general population. The valuation method was a discrete choice experiment containing 960 choice sets, i.e. pairs of QLU-C10D health states, each health state described in terms of the 10 QLU-C10D domains and the duration of that health state. Each participant considered 16 choice sets, choosing their preferred health state from each pair. Utility scores were derived using generalized estimation equation models. Non-monotonic levels were combined. RESULTS: Utility decrements were generated for all 10 QLU-C10D domains, with largest decrements for pain (- 0.242), physical functioning (- 0.228), and role functioning (- 0.149). Non-monotonic levels of emotional functioning, pain, fatigue, sleep problems, and appetite loss were combined. No decrement in utility was seen in case of a little or quite a bit impairment in emotional functioning or a little pain. The mean QLU-C10D utility score of the participants was 0.85 (median = 0.91, interquartile range = 0.82 to 0.96). CONCLUSION: Dutch utility decrements were generated for the QLU-C10D. These are important for evaluating the cost-utility of new cancer treatments and supportive care interventions. Further insight is warranted into the added value of the QLU-C10D alongside other utility instruments.
Entities:
Keywords:
Cancer; Discrete choice experiment; Quality of life; Utility
Authors: Helen McTaggart-Cowan; Madeleine T King; Richard Norman; Daniel S J Costa; A Simon Pickard; Rosalie Viney; Stuart J Peacock Journal: Health Qual Life Outcomes Date: 2022-06-16 Impact factor: 3.077